Opinion|Videos|April 17, 2024
Social Burden and Goals of Therapy for Patients with Bronchiectasis
A medical professional addresses the social aspects of bronchiectasis, emphasizing patients' embarrassment due to productive coughing in public spaces like grocery stores and churches, as well as the psychological challenges of planning travel and vacations due to the unpredictability of exacerbations, which can lead to social isolation.
Advertisement
Episodes in this series
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5